Characterization of 1′-Hydroxymidazolam Glucuronidation in Human Liver Microsomes
Open Access
- 12 November 2007
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Drug Metabolism and Disposition
- Vol. 36 (2), 331-338
- https://doi.org/10.1124/dmd.107.017962
Abstract
Midazolam is a potent benzodiazepine derivative with sedative, hypnotic, anticonvulsant, muscle-relaxant, and anxiolytic activities. It undergoes oxidative metabolism catalyzed almost exclusively by the CYP3A subfamily to a major metabolite, 1′-hydroxymidazolam, which is equipotent to midazolam. 1′-Hydroxymidazolam is subject to glucuronidation followed by renal excretion. To date, the glucuronidation of 1′-hydroxymidazolam has not been evaluated in detail. In the current study, we identified an unreported quaternary N-glucuronide, as well as the known O-glucuronide, from incubations of 1′-hydroxymidazolam in human liver microsomes enriched with uridine 5′-diphosphoglucuronic acid (UDPGA). The structure of the N-glucuronide was confirmed by nuclear magnetic resonance analysis, which showed that glucuronidation had occurred at N-2 (the imidazole nitrogen that is not a part of the benzodiazepine ring). In a separate study, in which midazolam was used as the substrate, an analogous N-glucuronide also was detected from incubations with human liver microsomes in the presence of UDPGA. Investigation of the kinetics of 1′-hydroxymidazolam glucuronidation in human liver microsomes indicated autoactivation kinetics (Hill coefficient, n = 1.2–1.5). The apparent S50 values for the formation of O- and N-glucuronides were 43 and 18 μM, respectively, and the corresponding apparent Vmax values were 363 and 21 pmol/mg of microsomal protein/min. Incubations with recombinant human uridine diphosphate glucuronosyltransferases (UGTs) indicated that the O-glucuronidation was catalyzed by UGT2B4 and UGT2B7, whereas the N-glucuronidation was catalyzed by UGT1A4. Consistent with these observations, hecogenin, a selective inhibitor of UGT1A4, selectively inhibited the N-glucuronidation, whereas diclofenac, a potent inhibitor of UGT2B7, had a greater inhibitory effect on the O-glucuronidation than on the N-glucuronidation. In summary, our study provides the first demonstration of N-glucuronidation of 1′-hydroxymidazolam in human liver microsomes.Keywords
This publication has 15 references indexed in Scilit:
- Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and LabelingClinical Pharmacology & Therapeutics, 2007
- 4-AminobiphenylN-glucuronidation by liver microsomes: optimization of the reaction conditions and characterization of the UDP-glucuronosyltransferase isoformsJournal of Applied Toxicology, 2006
- Quantitative 1H NMR: Development and Potential of a Method for Natural Products AnalysisJournal of Natural Products, 2004
- Possibility of Influence of Midazolam Sedation on the Diagnosis of Brain Death: Concentrations of Active Metabolites after Cessation of MidazolamYAKUGAKU ZASSHI, 2003
- Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac.Toxicological Sciences, 2001
- UDP-GlucuronosyltransferasesCurrent Drug Metabolism, 2000
- Specificity of human UDP-Glucuronosyltransferases and xenobiotic glucuronidationLife Sciences, 1995
- Prolonged sedation due to accumulation of conjugated metabolites of midazolamThe Lancet, 1995
- Midazolam A Review of its Pharmacological Properties and Therapeutic UseDrugs, 1984
- Pharmacokinetics and bioavailability of midazolam in man.British Journal of Clinical Pharmacology, 1983